Vaxcyte (PCVX) Net Equity Issued and Repurchased (2020 - 2025)

Vaxcyte (PCVX) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $264.2 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $264.2 million; the TTM figure through Dec 2025 stood at $264.2 million (up 34.84% YoY), while the FY2025 annual figure was $264.2 million, up 34.84% from the prior year.
• Net Equity Issued and Repurchased climbed to $264.2 million in Q1 2025 per PCVX's latest filing, from -$26000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $264.2 million in Q1 2025 and bottomed at -$46000.0 in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $50.9 million across 5 years, with a median of $41.8 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 1241.48% in 2023 and fell as far as 102.23% in 2023.
• Vaxcyte's Net Equity Issued and Repurchased stood at $6.8 million in 2021, then slumped by 69.64% to $2.1 million in 2022, then plunged by 102.23% to -$46000.0 in 2023, then soared by 43.48% to -$26000.0 in 2024, then jumped by 1016253.85% to $264.2 million in 2025.
• Business Quant data shows PCVX's Net Equity Issued and Repurchased at $264.2 million in Q1 2025, -$26000.0 in Q4 2024, and $89.5 million in Q3 2024.